Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study

Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism

(2020) Zeng Guo et al.   CLINICAL CHEMISTRY

ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials

(2020) Yaru Zhang et al.   DRUGS

Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism

(2020) Zeng Guo et al.   HYPERTENSION

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial

(2020) Hitoshi Minakuchi et al.   Scientific Reports

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

(2019) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

Addition of cyclic angiotensin-(1-7) to angiotensin converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.

(2019) Paola Cassis et al.   KIDNEY INTERNATIONAL

Counter-regulatory renin–angiotensin system in cardiovascular disease

(2019) Maria Paz Ocaranza et al.   Nature Reviews Cardiology

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

(2018) Rajiv Agarwal et al.   AMERICAN JOURNAL OF NEPHROLOGY

Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients

(2017) Johannes J. Kovarik et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

(2016) Xinfang Xie et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Angiotensin 1–7 Is a Negative Modulator of Aldosterone Secretion In Vitro and In VivoNovelty and Significance

(2016) Gabi Shefer et al.   HYPERTENSION

Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction

(2016) Noemi Pavo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney

(2016) Oliver Domenig et al.   Scientific Reports

An update of the blockade of the renin angiotensin aldosterone system in clinical practice

(2015) Diego F Márquez et al.   EXPERT OPINION ON PHARMACOTHERAPY

Angiotensin-(1-7) Prevents Angiotensin II-induced Fibrosis in Cremaster Microvessels

(2015) Kyle A. Carver et al.   MICROCIRCULATION

Molecular regulation of the renin–angiotensin system in haemodialysis patients

(2014) Johannes J. Kovarik et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Angiotensin-(1–7) in kidney disease: a review of the controversies

(2012) Danielle Zimmerman et al.   CLINICAL SCIENCE

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

(2012) Linda Shavit et al.   KIDNEY INTERNATIONAL

Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats

(2012) Jae Hee Ahn et al.   Diabetes & Metabolism Journal

Angiotensin Converting Enzyme 2, Angiotensin-(1-7), and Receptor Mas Axis in the Kidney

(2012) Sergio Veloso Brant Pinheiro et al.   International Journal of Hypertension

Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy

(2009) G. Y. Oudit et al.   DIABETES

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension

(2009) A Sato et al.   JOURNAL OF HUMAN HYPERTENSION